Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) saw its stock rise 11.4% after posting second-quarter results that topped Wall Street expectations and lifting its full-year revenue forecast, driven by continued momentum for its ARCALYST therapy.
The company reported adjusted earnings per share of $0.23 for the quarter, ahead of the $0.19 expected by analysts. Revenue came in at $156.79 million, surpassing the consensus estimate of $145.28 million and marking a 44.4% jump from $108.6 million in the same period last year. Growth was largely attributed to broader use of ARCALYST among patients with recurrent pericarditis.
“Our robust commercial performance in the second quarter was driven by expanding ARCALYST penetration across the recurrent pericarditis population, supported by growth among both new and repeat prescribers,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa.
Following the strong quarterly results, Kiniksa raised its 2025 net sales guidance for ARCALYST to a range of $625 million to $640 million, up from its prior estimate of $590 million to $605 million. The new midpoint of $632.5 million represents a 52% year-over-year increase and exceeds the analyst consensus of $604 million.
Since its launch, more than 3,475 prescribers have written prescriptions for ARCALYST to treat recurrent pericarditis, with patients remaining on treatment for an average of 30 months. As of the end of Q2, around 15% of the estimated 14,000 U.S. patients with multiple recurrences were actively using the therapy.
Kiniksa reported net income of $17.8 million for the quarter, reversing a net loss of $3.9 million in the same period last year. The company closed the quarter with $307.8 million in cash, cash equivalents, and short-term investments, held no debt, and expects to remain cash flow positive on a full-year basis.
Kiniksa Pharmaceuticals stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.